Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)
1 vistas
• 07/14/23
0
0
Empotrar
administrator
Suscriptores
Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios